Autolus Therapeutics plc Increase (Decrease) in Other Noncurrent Assets
Autolus Therapeutics plc (AUTL) reported Increase (Decrease) in Other Noncurrent Assets of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentAssets · last filed 2026-03-27
- Autolus Therapeutics plc increase (decrease) in other noncurrent assets for the quarter ending 2024-12-31 was -$5.00K.
- Autolus Therapeutics plc increase (decrease) in other noncurrent assets for the quarter ending 2024-09-30 was $0.00.
- Autolus Therapeutics plc increase (decrease) in other noncurrent assets for the quarter ending 2024-06-30 was $0.00.
- Autolus Therapeutics plc increase (decrease) in other noncurrent assets for the quarter ending 2024-03-31 was $0.00.
- Autolus Therapeutics plc increase (decrease) in other noncurrent assets for fiscal 2025 was $0.00.
- Autolus Therapeutics plc increase (decrease) in other noncurrent assets for fiscal 2024 was -$5.00K.
- Autolus Therapeutics plc increase (decrease) in other noncurrent assets for fiscal 2023 was -$937.00K, a 18840.00% decline from fiscal 2022.
- Autolus Therapeutics plc increase (decrease) in other noncurrent assets for fiscal 2022 was $5.00K.
| Period end | Increase (Decrease) in Other Noncurrent Assets 3 month | Increase (Decrease) in Other Noncurrent Assets 6 month | Increase (Decrease) in Other Noncurrent Assets 9 month | Increase (Decrease) in Other Noncurrent Assets 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-27 | |||
| 2024-12-31 | -$5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$5.00K derived: sum of 2 quarters · filed 2026-03-27 | -$5.00K derived: sum of 3 quarters · filed 2026-03-27 | -$5.00K 10-K · filed 2026-03-27 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | $0.00 derived: sum of 4 quarters · filed 2025-03-20 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | $0.00 derived: sum of 3 quarters · filed 2025-03-20 | -$886.00K derived: sum of 4 quarters · filed 2025-03-20 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-17 | $0.00 derived: sum of 2 quarters · filed 2025-03-20 | -$886.00K derived: sum of 3 quarters · filed 2025-03-20 | -$886.00K derived: sum of 4 quarters · filed 2025-03-20 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$886.00K derived: sum of 2 quarters · filed 2025-03-20 | -$886.00K derived: sum of 3 quarters · filed 2025-03-20 | -$937.00K 10-K · filed 2025-03-20 |
| 2023-09-30 | -$886.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$886.00K derived: sum of 2 quarters · filed 2024-11-12 | -$937.00K 10-Q · filed 2024-11-12 | -$937.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$51.00K 10-Q · filed 2024-08-08 | -$51.00K derived: sum of 3 quarters · filed 2024-08-08 | |
| 2023-03-31 | -$51.00K 10-Q · filed 2024-05-17 | -$51.00K derived: sum of 2 quarters · filed 2024-05-17 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $5.00K 10-K · filed 2024-03-21 | ||
| 2022-09-30 | $5.00K 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | -$575.00K 10-K · filed 2024-03-21 | |||
| 2021-03-31 | -$811.00K 6-K · filed 2021-05-06 | -$758.00K derived: sum of 2 quarters · filed 2023-03-07 | -$758.00K derived: sum of 3 quarters · filed 2023-03-07 | -$321.00K derived: sum of 4 quarters · filed 2023-03-07 |
| 2020-12-31 | $53.00K derived: 20-F 12 month − 6-K 9 month · filed 2023-03-07 | $53.00K derived: sum of 2 quarters · filed 2023-03-07 | $490.00K derived: sum of 3 quarters · filed 2023-03-07 | $508.00K 20-F · filed 2023-03-07 |
| 2020-09-30 | $0.00 derived: 6-K 9 month − 6-K 6 month · filed 2020-11-05 | $437.00K derived: sum of 2 quarters · filed 2020-11-05 | $455.00K 6-K · filed 2020-11-05 | $433.00K derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-06-30 | $437.00K derived: 6-K 6 month − 6-K 3 month · filed 2020-08-06 | $455.00K 6-K · filed 2020-08-06 | $433.00K derived: sum of 3 quarters · filed 2022-03-10 | $443.00K derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-03-31 | $18.00K 6-K · filed 2021-05-06 | -$4.00K derived: sum of 2 quarters · filed 2022-03-10 | $6.00K derived: sum of 3 quarters · filed 2022-03-10 | $13.00K derived: sum of 4 quarters · filed 2022-03-10 |
| 2019-12-31 | -$22.00K derived: 20-F 12 month − 6-K 9 month · filed 2022-03-10 | -$12.00K derived: sum of 2 quarters · filed 2022-03-10 | -$5.00K derived: sum of 3 quarters · filed 2022-03-10 | $702.00K 20-F · filed 2022-03-10 |
| 2019-09-30 | $10.00K derived: 6-K 9 month − 6-K 6 month · filed 2020-11-05 | $17.00K derived: sum of 2 quarters · filed 2020-11-05 | $724.00K 6-K · filed 2020-11-05 | $2.01M derived: sum of 4 quarters · filed 2021-03-04 |
| 2019-06-30 | $7.00K derived: 6-K 6 month − 6-K 3 month · filed 2020-08-06 | $714.00K 6-K · filed 2020-08-06 | $2.00M derived: sum of 3 quarters · filed 2021-03-04 | $2.00M derived: sum of 4 quarters · filed 2021-03-04 |
| 2019-03-31 | $707.00K 6-K · filed 2020-05-07 | $1.99M derived: sum of 2 quarters · filed 2021-03-04 | $1.99M derived: sum of 3 quarters · filed 2021-03-04 | |
| 2018-12-31 | $1.28M 20-F · filed 2021-03-04 | $1.28M derived: sum of 2 quarters · filed 2021-03-04 | ||
| 2018-09-30 | $0.00 derived: 20-F 9 month − 6-K 6 month · filed 2021-03-04 | $0.00 20-F · filed 2021-03-04 | $0.00 20-F · filed 2020-03-03 | |
| 2018-06-30 | $0.00 6-K · filed 2019-08-08 | |||
| 2017-09-30 | $0.00 20-F · filed 2020-03-03 | |||
| 2016-09-30 | $0.00 20-F · filed 2019-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 |